Manning & Napier Group's PTCT Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 125 shares of PTC Therapeutics, Inc. (PTCT) worth $9,524, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Manning & Napier Group has initiated a new position in PTCT, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +125 | New Buy | 125 | $76.19 |
Manning & Napier Group's PTC Therapeutics Investment FAQs
Manning & Napier Group first purchased PTC Therapeutics, Inc. (PTCT) in Q4 2025, acquiring 125 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held PTC Therapeutics, Inc. (PTCT) for 1 quarters since Q4 2025.
Manning & Napier Group's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q4 2025, adding 125 shares worth $9,524.
According to the latest 13F filing for Q4 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 125 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $9,524.
As of the Q4 2025 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in PTC Therapeutics, Inc. (PTCT) was 125 shares, as reported at the end of Q4 2025.